Stem cell showdown: Small business versus the FDA

| January 15, 2013 |
Credit: Thomas Prior for Bloomberg Businessweek Credit: Thomas Prior for Bloomberg Businessweek

In Texas, the science of stem cells has collided with a governor’s ambitions, a businessman’s optimism, a doctor’s faith, and patients’ hopes. Stem cells hold enormous promise, but promise isn’t proof, and anecdotal evidence isn’t science. Small companies often can’t do the research required by the FDA and make money at the same time. Some patients will pay to be part of an experiment, but many doctors and regulators don’t think they should.

View the full article here: Stem Cell Showdown: Celltex vs. the FDA